

CCR Translations

- Has Quantitative Multimodal Imaging of Treatment Response Arrived?**
Thomas E. Yankeelov and John C. Gore6473
□□ *Commentary on O'Connor et al., p. 6674*
- Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment.**
Mary L. Disis6476
□□ *Commentary on Ueda et al., p. 6551 and Terabe et al., p. 6560*

Molecular Pathways

- MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities.**
Chi V. Dang, Anne Le, and Ping Gao6479
- Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors.** Shao-Chun Wang and Mien-Chie Hung.....6484

Perspective

- Metabolic Approaches to Treatment of Melanoma.** Peter Hersey, Ralph Neal Watts, Xu Dong Zhang, and John Hackett6490

Reviews

- The p53 Family Protein p73 Provides New Insights into Cancer Chemosensitivity and Targeting.** Paolo Lunghi, Antonio Costanzo, Laura Mazzera, Vittorio Rizzoli, Massimo Levrero, and Antonio Bonati6495
- T Cell-Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective.** Alaaeldin Shablak, Robert E. Hawkins, Dominic G. Rothwell, and Eyad Elkord.....6503

Human Cancer Biology

- Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer.** Fabian Mc. Johnston, Marcus C.B. Tan, Benjamin R. Tan, Jr., Matthew R. Porembka, Elizabeth M. Brunt, David C. Linehan, Peter O. Simon, Jr., Stacey Plambeck-Suess, Timothy J. Eberlein, Karl Erik Hellstrom, Ingegerd Hellstrom, William G. Hawkins, and Peter Goedegebuure6511
- Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells.** Steven L. Warner, Bret J. Stephens, Stanley Nwokenkwo, Galen Hostetter, Anastasia Sugeng, Manuel Hidalgo, Jeffery M. Trent, Haiyong Han, and Daniel D. Von Hoff6519
- Cross-Talk between Estrogen Receptor and Epidermal Growth Factor Receptor in Head and Neck Squamous Cell Carcinoma.** Ann Marie Egloff, Mary E. Rothstein, Raja Seethala, Jill M. Siegfried, Jennifer Rubin Grandis, and Laura P. Stabile.....6529
- Genomic and Expression Profiling of Glioblastoma Stem Cell-Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival.** Aurélie Ernst, Stefanie Hofmann, Rezvan Ahmadi, Natalia Becker, Andrey Korshunov, Felix Engel, Christian Hartmann, Jörg Felsberg, Michael Sabel, Heike Peterziel, Moritz Durchdewald, Jochen Hess, Sebastian Barbus, Benito Campos, Anna Starzinski-Powitz, Andreas Unterberg, Guido Reifenberger, Peter Lichter, Christel Herold-Mende, and Bernhard Radlwimmer.....6541

Cancer Therapy: Preclinical

- Systemic Inhibition of Transforming Growth Factor- β in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines.** Ryo Ueda, Mitsugu Fujita, Xinmei Zhu, Kotaro Sasaki, Edward R. Kasthuber, Gary Kohanbash, Heather A. McDonald, Jay Harper, Scott Lonning, and Hideho Okada.....6551

Synergistic Enhancement of CD8⁺ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-β Monoclonal Antibody. Masaki Terabe, Elena Ambrosino, Shun Takaku, Jessica J. O'Konek, David Venzon, Scott Lonning, John M. McPherson, and Jay A. Berzofsky	6560
Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance. Jonna Nevo, Elina Mattila, Teijo Pellinen, Daniel L. Yamamoto, Henri Sara, Kristiina Iljin, Olli Kallioniemi, Petri Bono, Päivi Heikkilä, Heikki Joensuu, Anni Wärrä, and Johanna Ivaska	6570
Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions. Mario I. Vega, Sara Huerta-Yepe, Melisa Martinez-Paniagua, Bernardo Martinez-Miguel, Rogelio Hernandez-Pando, Cesar R. González-Bonilla, Paul Chinn, Nabil Hanna, Kandasamy Hariharan, Ali R. Jazirehi, and Benjamin Bonavida.....	6582
Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter. Inge Peerlinck, Andrew Merron, Patrick Baril, Sophie Conchon, Pilar Martin-Duque, Cécilia Hindorf, Jerome Burnet, Miguel Quintanilla, Mohan Hingorani, Richard Iggo, Nick R. Lemoine, Kevin Harrington, and Georges Vassaux.....	6595
Interferon-γ-Dependent Infiltration of Human T Cells into Neuroblastoma Tumors <i>In vivo</i>. Gregor S.D. Reid, Xiaochuan Shan, Christina M. Coughlin, Wiem Lassoued, Bruce R. Pawel, Leonard H. Wexler, Carol J. Thiele, Maria Tsokos, Jack L. Pinkus, Geraldine S. Pinkus, Stephan A. Grupp, and Robert H. Vonderheide.....	6602
SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity <i>In vitro</i> and <i>In vivo</i>. Patrick Roth, Maria Kissel, Caroline Herrmann, Günter Eisele, Johann Leban, Michael Weller, and Friederike Schmidt	6609
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts. Aoife M. Shannon, Brian A. Telfer, Paul D. Smith, Muhammed Babur, Armelle Logie, Robert W. Wilkinson, Camille Debray, Ian J. Stratford, Kaye J. Williams, and Stephen R. Wedge.....	6619
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Wei Wang, Qi Li, Tadaaki Yamada, Kunio Matsumoto, Isao Matsumoto, Makoto Oda, Go Watanabe, Yoshiyuki Kayano, Yasuhiko Nishioka, Saburo Sone, and Seiji Yano.....	6630
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Dongwei Zhang, Tiffany A. LaFortune, Savitri Krishnamurthy, Francisco J. Esteva, Massimo Cristofanilli, Ping Liu, Anthony Lucci, Balraj Singh, Mien-Chie Hung, Gabriel N. Hortobagyi, and Naoto T. Ueno	6639

Imaging, Diagnosis, Prognosis

Altered Tissue 3'-Deoxy-3'-[¹⁸F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography. Laura M. Kenny, Kaiyumars B. Contractor, Justin Stebbing, Adil Al-Nahas, Carlo Palmieri, Sami Shousha, R. Charles Coombes, and Eric O. Aboagye	6649
Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer. David A. Brown, Fredrik Lindmark, Pär Stattin, Katarina Bälter, Hans-Olov Adami, Sigun L. Zheng, Jianfeng Xu, William B. Isaacs, Henrik Grönberg, Samuel N. Breit, and Fredrik E. Wiklund.....	6658
Regional Brain Activation during Verbal Declarative Memory in Metastatic Breast Cancer. Shelli R. Kesler, F. Chris Bennett, Misty L. Mahaffey, and David Spiegel.....	6665

Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging. James P.B. O'Connor, Richard A.D. Carano, Andrew R. Clamp, Jed Ross, Calvin C.K. Ho, Alan Jackson, Geoff J.M. Parker, Chris J. Rose, Franklin V. Peale, Michel Friesenhahn, Claire L. Mitchell, Yvonne Watson, Caleb Roberts, Lynn Hope, Sue Cheung, Hani Bou Reslan, Mary Ann T. Go, Glenn J. Pacheco, Xiumin Wu, Tim C. Cao, Sarajane Ross, Giovanni A. Buonaccorsi, Karen Davies, Jurjees Hasan, Paula Thornton, Olivia del Puerto, Napoleone Ferrara, Nicholas van Bruggen, and Gordon C. Jayson6674

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients. Jörg Felsberg, Marion Rapp, Simon Loeser, Rolf Fimmers, Walter Stummer, Matthias Goepfert, Hans-Jacob Steiger, Britta Friedensdorf, Guido Reifenberger, and Michael C. Sabel6683

Cancer Therapy: Clinical

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors. Roger B. Cohen, Suzanne F. Jones, Charu Aggarwal, Margaret von Mehren, Jonathan Cheng, David R. Spigel, F. Anthony Greco, Mariangela Mariani, Maurizio Rocchetti, Roberta Ceruti, Silvia Comis, Bernard Laffranchi, Jurgen Moll, and Howard A. Burris6694

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies. Howard A. Burris III, Charles W. Taylor, Suzanne F. Jones, Kevin M. Koch, Melissa J. Versola, Niki Arya, Ronald A. Fleming, Deborah A. Smith, Lini Pandite, Neil Spector, and George Wilding6702

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers. Rebecca A. Herbertson, Niall C. Tebbutt, Fook-Thean Lee, David J. MacFarlane, Bridget Chappell, Noel Micallef, Sze-Ting Lee, Timothy Saunder, Wendie Hopkins, Fiona E. Smyth, David K. Wyld, John Bellen, Daryl S. Sonnichsen, Martin W. Brechbiel, Carmel Murone, and Andrew M. Scott6709

Serum Molecular Signatures of Weight Change during Early Breast Cancer Chemotherapy. Hector C. Keun, Jasmin Sidhu, Dmitry Pchejetski, Jacqueline S. Lewis, Helena Marconell, Michael Patterson, Steven R. Bloom, Vian Amber, R. Charles Coombes, and Justin Stebbing6716

In vitro and Clinical Studies of Gene Therapy with Recombinant Human Adenovirus-p53 Injection for Oral Leukoplakia. Yi Li, Long-Jiang Li, Song-Tao Zhang, Li-Juan Wang, Zhuang Zhang, Ning Gao, Yuan-Yuan Zhang, and Qian-Ming Chen6724

A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia. Alexander E. Perl, Margaret T. Kasner, Donald E. Tsai, Dan T. Vogl, Alison W. Loren, Stephen J. Schuster, David L. Porter, Edward A. Stadtmauer, Steven C. Goldstein, Noelle V. Frey, Sunita D. Nasta, Elizabeth O. Hexner, Jamil K. Dierov, Cezary R. Swider, Adam Bagg, Alan M. Gewirtz, Martin Carroll, and Selina M. Luger6732

Letters to the Editor

Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3-Positive Lymphatic/Vascular Endothelial Progenitor Cells. Francoise Farace, Melissa Taylor, Jochen Rössler, Yohann Loriot, and Benjamin Besse6740

In Response. Krisztina Bogos, Ferenc Renyi-Vamos, Judit Dobos, Jozsef Tovari, Gyula Ostoros, and Balazs Dome6740

Gene Expression Profiling for Discovery of Novel Markers of Minimal Disease. Virginie F. Viprey and Susan A. Burchill6742


In Response. Irene Y. Cheung and Nai-Kong V. Cheung6743

Correction

Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study6744

About the Cover

A recombinant adenovirus genetically designed to replicate in colorectal carcinoma cells was engineered to express the Na/I symporter in target cells only. In vivo, SPECT imaging was used to monitor the propagation of the virus in tumors and to establish the ideal timing for metabolic radiotherapy. For further details, please see the article by Peerlinck and co-workers on page 6595 in this issue.



Clinical Cancer Research

15 (21)

Clin Cancer Res 2009;15:6473-6744.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/15/21>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/15/21>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.